Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model
Kamrul Islam, Fekade B. Sime, Steven C. Wallis, Michelle J. Bauer, Saiyuri Naicker, Hayoung Won, Hosam M. Zowawi, M. A. Choudhury, Tahmina Shirin, Zakir Hossain Habib, Patrick N. A. Harris, Meerjady Sabrina Flora, Jason A. Roberts
Abstract
Carbapenems are recommended for the treatment of urosepsis caused by extended-spectrum β-lactamase (ESBL)-producing, multidrug-resistant Escherichia coli ; however, due to selection of carbapenem resistance, there is an increasing interest in alternative treatment regimens including the use of β-lactam-aminoglycoside combinations. We compared the pharmacodynamic activity of piperacillin-tazobactam and amikacin as mono and combination therapy versus meropenem monotherapy against extended-spectrum β-lactamase (ESBL)-producing, piperacillin-tazobactam resistant E. coli using a dynamic hollow fiber infection model (HFIM) over 7 days.